RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib

MT Newswires Live09-30

RedHill Biopharma (RDHL) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVID-19.

The patent from the US Patent and Trademark Office would be granted on Oct. 15 and be valid through 2041, the company said.

The patent is based on post-hoc data from opaganib's phase 2/3 study that showed that patients with up to 60% fraction of inspired oxygen levels had better outcomes at day 14 of opaganib treatment compared with placebo, RedHill said.

The outcomes include more patients no longer requiring supplemental oxygen by day 14, a reduction in intubation/mechanical ventilation, and a "clinically meaningful" reduction in mortality, the company said.

Shares of RedHill were up 2.8% in premarket activity on Monday.

Price: 8.87, Change: +0.24, Percent Change: +2.82

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471680251?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471680251","market":"hk","top_or_hot":-1,"title":"RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib","media":"MT Newswires Live","content":"<html><body><p> RedHill Biopharma (RDHL) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVID-19.</p><p>The patent from the US Patent and Trademark Office would be granted on Oct. 15 and be valid through 2041, the company said.</p><p>The patent is based on post-hoc data from opaganib's phase 2/3 study that showed that patients with up to 60% fraction of inspired oxygen levels had better outcomes at day 14 of opaganib treatment compared with placebo, RedHill said.</p><p>The outcomes include more patients no longer requiring supplemental oxygen by day 14, a reduction in intubation/mechanical ventilation, and a \"clinically meaningful\" reduction in mortality, the company said.</p><p>Shares of RedHill were up 2.8% in premarket activity on Monday.</p><p>Price: 8.87, Change: +0.24, Percent Change: +2.82</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 20:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RedHill Biopharma (RDHL) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2471680251","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471680251","pubTimestamp":1727699642,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"RedHill Biopharma (RDHL) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RDHL":"Redhill Biopharma Ltd"},"translate_title":"RedHill Biopharma表示美国为Opaganib颁发了新冠病毒专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDHL":0.9},"content_text":"RedHill Biopharma (RDHL) said Monday that the US has issued a new patent for identifying a novel biomarker of coronavirus pneumonia prognostic for potential opaganib efficacy for the treatment of COVID-19.The patent from the US Patent and Trademark Office would be granted on Oct. 15 and be valid through 2041, the company said.The patent is based on post-hoc data from opaganib's phase 2/3 study that showed that patients with up to 60% fraction of inspired oxygen levels had better outcomes at day 14 of opaganib treatment compared with placebo, RedHill said.The outcomes include more patients no longer requiring supplemental oxygen by day 14, a reduction in intubation/mechanical ventilation, and a \"clinically meaningful\" reduction in mortality, the company said.Shares of RedHill were up 2.8% in premarket activity on Monday.Price: 8.87, Change: +0.24, Percent Change: +2.82","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471680251"}